Literature DB >> 27062086

Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.

Aliya M S El Newahie1, Nasser S M Ismail2, Dalal A Abou El Ella3, Khaled A M Abouzid3.   

Abstract

Quinoxaline derivatives, also called benzopyrazines, are an important class of heterocyclic compounds. Quinoxalines have drawn great attention due to their wide spectrum of biological activities. They are considered as an important basis for anticancer drugs due to their potential activity as protein kinase inhibitors. In this review, we focus on the chemistry of the quinoxaline derivatives, the strategies for their synthesis, their potential activities against various tyrosine kinases, and on the structure-activity relationship studies reported to date.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Anticancer; Kinase inhibitors; Quinoxalines; SAR; Synthetic strategies

Mesh:

Substances:

Year:  2016        PMID: 27062086     DOI: 10.1002/ardp.201500468

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  8 in total

1.  K2S2O8 mediated C-3 arylation of quinoxalin-2(1H)-ones under metal-, photocatalyst- and light-free conditions.

Authors:  Nibedita Baruah Dutta; Mayurakhi Bhuyan; Gakul Baishya
Journal:  RSC Adv       Date:  2020-01-22       Impact factor: 4.036

2.  Convenient Synthesis and Anticancer Activity of Methyl 2-[3-(3-Phenyl-quinoxalin-2-ylsulfanyl)propanamido]alkanoates and N-Alkyl 3-((3-Phenyl-quinoxalin-2-yl)sulfanyl)propanamides.

Authors:  Samir M El Rayes; Ahmed Aboelmagd; Mohamed S Gomaa; Ibrahim A I Ali; Walid Fathalla; Faheem H Pottoo; Firdos A Khan
Journal:  ACS Omega       Date:  2019-10-28

3.  Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors.

Authors:  Mathias Elsocht; Philippe Giron; Laila Maes; Wim Versées; Gustavo J Gutierrez; Jacques De Grève; Steven Ballet
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

4.  Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.

Authors:  Sha-Sha Cheng; Yuan-Qing Qu; Jia Wu; Guan-Jun Yang; Hao Liu; Wanhe Wang; Qi Huang; Feng Chen; Guodong Li; Chun-Yuen Wong; Vincent Kam Wai Wong; Dik-Lung Ma; Chung-Hang Leung
Journal:  Acta Pharm Sin B       Date:  2021-10-30       Impact factor: 14.903

5.  Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds.

Authors:  Kamonpan Sanachai; Panupong Mahalapbutr; Lueacha Tabtimmai; Supaphorn Seetaha; Tanakorn Kittikool; Sirilata Yotphan; Kiattawee Choowongkomon; Thanyada Rungrotmongkol
Journal:  ACS Omega       Date:  2022-09-07

6.  Design, Synthesis, and Molecular Docking Studies of Some New Quinoxaline Derivatives as EGFR Targeting Agents.

Authors:  Vinitha Badithapuram; Satheesh Kumar Nukala; Narasimha Swamy Thirukovela; Gouthami Dasari; Ravinder Manchal; Srinivas Bandari
Journal:  Russ J Bioorg Chem       Date:  2022-06-21       Impact factor: 1.254

7.  Convenient Synthesis of N-Alkyl-2-(3-phenyl-quinoxalin-2-ylsulfanyl)acetamides and Methyl-2-[2-(3-phenyl-quinoxalin-2-ylsulfanyl)acetylamino]alkanoates.

Authors:  Samir Mohamed El Rayes; Gaber El-Enany; Mohamed Sayed Gomaa; Ibrahim A I Ali; Walid Fathalla; Faheem Hyder Pottoo; Firdos Alam Khan
Journal:  ACS Omega       Date:  2022-09-15

8.  Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment.

Authors:  Manvendra Kumar; Gaurav Joshi; Sahil Arora; Tashvinder Singh; Sajal Biswas; Nisha Sharma; Zahid Rafiq Bhat; Kulbhushan Tikoo; Sandeep Singh; Raj Kumar
Journal:  Molecules       Date:  2021-03-09       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.